DOCTIS Project’s Post

In this AJMC - The American Journal of Managed Care interview, Dr Jeff Stark, vice president and head of medical immunology at UCB, shares new insights on the long-term benefits of bimekizumab-bkzx in managing patients with moderate to severe hidradenitis suppurativa (HS). Pain and draining tunnels are key challenges for patients with HS, significantly impacting their quality of life. Addressing acute inflammation and long-term consequences is crucial for enhancing patient well-being and daily functioning. Data presented at the American Academy of Dermatology found that 50% of patients treated with bimekizumab-bkzx achieved no draining tunnels by week 48. Watch here! https://lnkd.in/esZAjPPc #Dermatology #HidradenitisSuppurativa #Bimekizumab #MedicalResearch #HealthcareInnovation #ChronicIllness #PatientCare #PainManagement #QualityofLife #AAD2024

Exciting news on the horizon! The Immune-Mediated Inflammatory Disease Forum is gearing up for a website transformation. As we have expanded our platform into a resource that delves beyond rheumatology into dermatology and gastroenterology, the IMID Forum is your go-to hub for a comprehensive understanding of immune-mediated inflammatory diseases. #IMID #Rheumatology #Dermatology #Gastroenterology

Under the motto “Uncovering the Broad Spectrum of Psoriatic Disease” the 7th World Psoriasis & Psoriatic Arthritis Conference took place last week in Stockholm. The focus of the conference is to improve the lives of patients living with psoriatic disease by sharing significant achievements in the prevention, diagnosis, and treatment. With PsorX-LabDisk, we support dermatopathologists in the differential diagnosis of psoriasis and eczema - as there are still up to 50% misdiagnoses of the two skin diseases due to overlapping clinical and histological appearances. However, the feedback from the dermatologists at the conference was clear: ❗This is not enough❗The test needs to be introduced into dermatologists' practices for use at the point of care. How good that work on it is already in full swing in the Dermagnostix R&D team!💪🚀 This feedback once again reinforces our belief in the urgent need for molecular diagnostics for inflammatory skin diseases - both for dermatologists and pathologists. 💡You want to be part of the #DermagnosticFuture? Schedule a meeting with us now to learn more about PsorX: https://lnkd.in/egn75BGc #MolecularDiagnostics #Psoriasis #PsorX #Dermatology #Innovation #IFPA

💡Psoriasis Treatment is Evolving! 💡 Spherix Global Insights highlights the excitement around pipeline agents like Johnson & Johnson’s oral IL-23 asset, JNJ-2113, which reflects high expectations for it to capture significant market share, potentially outpacing other oral candidates and shifting the timelines for initiating biologic treatments. Competing with JNJ-2113 in the pipeline are several promising TYK2 inhibitors, including ESK-001 from Alumis, zasocitinib (TAK-279) from Takeda, and BMS-986322 from Bristol Myers Squibb. With patient preference shifting towards oral options, these innovative treatments could reshape the market and improve care. Read more: https://lnkd.in/e4JfAKMy #Psoriasis #Dermatology #EmergingTherapies #MarketResearch

📢📰Another recent published paper, further displaying the many and varied capabilities for which Porsolt is known 💪 #porsolt #cro #preclinicalresearch #psoriasis #inflammation #autoimmune #quality #dermatology

In honor of Eczema Awareness Month, we’re spotlighting atopic dermatitis (AD) and new advancements in its management. 💡 Our latest CME activity, A New Wave of Topical Therapies for Atopic Dermatitis: Comparing Treatment Approaches, led by Dr. Peter Lio and Dr. Lisa Swanson, dives into the latest clinical data on current and emerging AD therapies. This educational session also covers strategies for treatment selection, long-term disease control, and overcoming treatment challenges. Learning Objectives: 1️⃣ Critically evaluate clinical data and mechanisms of AD therapies 2️⃣ Identify and overcome challenges in topical AD treatments 3️⃣ Develop individualized topical therapy strategies for AD patients 🔗Advance your AD expertise here: https://lnkd.in/eFZDCf2J #EczemaAwarenessMonth #AtopicDermatitis #AD #Eczema #CME #CE #Dermatology #LiVDerm

Excited to share that I co-authored a poster being presented at the EADV Congress 2024 here in Amsterdam, showcasing phase 3 clinical trial results for secukinumab in treating hidradenitis suppurativa. The data show significant clinical improvement independently of the lesion type at baseline. However, the highest clinical responses were seen for patients with inflammatory nodules only at baseline, highlighting secukinumab’s broad efficacy across different lesion types but reinforcing the need to treat early on disease course. A promising step forward in addressing this challenging condition! #EADV2024 European Academy of Dermatology and Venereology #HidradenitisSuppurativa #ClinicalTrials #Dermatology #immunology

Which medical specialties do you think are most researched? M3’s panel team recently shared a blog highlighting the top six specialties that are currently in high demand for paid surveys. Topping the list are: 1. Oncology and haematology 2. Cardiology 3. Dermatology Find out which other specialties made the top spots and what impacts the availability of paid medical surveys > https://hubs.ly/Q02sGJCf0 #Marketresearch #Healthcare #MedicalSpecialties #Paidsurveys #Oncology #Haematology #Cardiology #Dermatology

🎉 Excited to share that a groundbreaking study from Kyle Lauck at Baylor University Medical Center on sexual dysfunction (SD) associated with 5-alpha-reductase inhibitors (5-ARIs) in androgenetic alopecia (AGA) patients has won the prestigious Fox Award! 🏆 This global retrospective cohort study, leveraging data from 120 million patients via the TriNetX network, provides critical insights into the prevalence of SD in AGA patients treated with 5-ARIs. Key findings include a modest absolute risk increase of SD in patients on 5-ARIs, particularly with finasteride 5 mg, and a significant correlation with comorbidities such as obesity, diabetes, and hypertension. This study underscores the importance of considering comorbid factors when evaluating SD risk in AGA treatments and paves the way for more nuanced patient care strategies. 👉 Read the full study here: https://lnkd.in/dhF-x8pd #research #healthcare #androgeneticalopecia #sexualdysfunction #5ARIs #TriNetX #FoxAward

📰 Porsolt is proud to announce our most recent paper on Psoriasis, published in the International Journal of Molecular Sciences MDPI. ✨ Many thanks to the Porsolt team for their hard work and commitment to the preclinical scientific research. 👉 Get a glimpse of our scientific advancements in a few slides. ______________ Contact us to learn more about our capabilities in psoriasis, inflammation, dermatology, autoimmune diseases, and many other areas: ✉ contact@porsolt.com 🌐 www.porsolt.com #porsolt #cro #preclinicalresearch #psoriasis #inflammation #autoimmune #dermatology #quality #histology #biomarkers